Munich Reinsurance Co Stock Corp in Munich Sells 89,532 Shares of Solventum Corporation $SOLV

Munich Reinsurance Co Stock Corp in Munich lowered its stake in shares of Solventum Corporation (NYSE:SOLV) by 73.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 31,890 shares of the company’s stock after selling 89,532 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich’s holdings in Solventum were worth $2,460,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the stock. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Solventum during the 2nd quarter valued at $150,066,000. SG Americas Securities LLC boosted its stake in shares of Solventum by 38.4% in the 1st quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock worth $8,467,000 after buying an additional 35,982 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Solventum by 0.6% in the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock worth $93,561,000 after acquiring an additional 9,083 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Solventum in the second quarter worth $61,460,000. Finally, First Trust Advisors LP increased its position in Solventum by 57.4% during the first quarter. First Trust Advisors LP now owns 334,441 shares of the company’s stock valued at $21,839,000 after acquiring an additional 121,989 shares during the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the topic of a number of recent research reports. KeyCorp increased their target price on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Mizuho set a $113.00 price target on shares of Solventum in a research report on Thursday, August 6th. Stifel Nicolaus upped their price target on shares of Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wedbush increased their price objective on shares of Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.64.

Solventum Price Performance

Shares of Solventum stock opened at $91.70 on Friday. Solventum Corporation has a one year low of $62.38 and a one year high of $94.16. The stock’s fifty day moving average is $84.00 and its 200 day moving average is $76.01. The stock has a market cap of $15.61 billion, a P/E ratio of 11.21, a P/E/G ratio of 1.44 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02.

Solventum (NYSE:SOLV) last released its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same period in the previous year, the business earned $1.69 earnings per share. Solventum’s quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Sell-side analysts anticipate that Solventum Corporation will post 7.22 earnings per share for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.